Is WHWK or BOLD more profitable?

Boundless Bio's return on equity of -53.60% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Boundless Bio N/A -53.60% -34.66%

Does the media refer more to WHWK or BOLD?

In the previous week, Boundless Bio had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Whitehawk Therapeutics. Boundless Bio's average media sentiment score of 1.25 beat Whitehawk Therapeutics' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TTRX or BOLD?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Boundless Bio N/A N/A -$58.20M -$2.50 N/A

Is TTRX or BOLD more profitable?

Turn Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Boundless Bio N/A -53.60% -34.66%

Does the media prefer TTRX or BOLD?

In the previous week, Boundless Bio had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Boundless Bio and 2 mentions for Turn Therapeutics. Boundless Bio's average media sentiment score of 1.25 beat Turn Therapeutics' score of 0.46 indicating that Boundless Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BOLD or CNTN?

Boundless Bio presently has a consensus target price of $4.00, suggesting a potential upside of 60.00%. Given Boundless Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Boundless Bio is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BOLD or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.50 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is BOLD or CNTN more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Hillstream Biopharma N/A -31.50% -24.72%

Does the media prefer BOLD or CNTN?

In the previous week, Boundless Bio had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Hillstream Biopharma. Boundless Bio's average media sentiment score of 1.25 beat Hillstream Biopharma's score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, BOLD or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.50 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is BOLD or ANTX more profitable?

Anthem's return on equity of -52.35% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Anthem N/A -52.35% -47.25%

Is BOLD or SPRB more profitable?

Boundless Bio's return on equity of -53.60% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Spruce Biosciences N/A -155.40% -101.67%

Does the media refer more to BOLD or SPRB?

In the previous week, Boundless Bio had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Spruce Biosciences. Boundless Bio's average media sentiment score of 1.25 beat Spruce Biosciences' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Boundless Bio (BOLD) Competitors

$2.50 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.61 +0.11 (+4.36%)

As of 07/2/2026 07:58 PM Eastern

Compare

BOLD vs. WHWK, TTRX, CNTN, ANTX, and SPRB

Should you buy Boundless Bio stock or one of its competitors? MarketBeat compares Boundless Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Boundless Bio include Whitehawk Therapeutics (WHWK), Turn Therapeutics (TTRX), Hillstream Biopharma (CNTN), Anthem (ANTX), and Spruce Biosciences (SPRB).

How does Boundless Bio compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Whitehawk Therapeutics has higher revenue and earnings than Boundless Bio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

Boundless Bio's return on equity of -53.60% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Boundless Bio	N/A	-53.60%	-34.66%

Whitehawk Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 90.93%. Boundless Bio has a consensus price target of $4.00, indicating a potential upside of 60.00%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Whitehawk Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Boundless Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Boundless Bio had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Whitehawk Therapeutics. Boundless Bio's average media sentiment score of 1.25 beat Whitehawk Therapeutics' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Whitehawk Therapeutics beats Boundless Bio on 9 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Boundless Bio had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Boundless Bio and 2 mentions for Turn Therapeutics. Boundless Bio's average media sentiment score of 1.25 beat Turn Therapeutics' score of 0.46 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 12.36%. Boundless Bio has a consensus price target of $4.00, suggesting a potential upside of 60.00%. Given Boundless Bio's higher probable upside, analysts plainly believe Boundless Bio is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Turn Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

Turn Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Boundless Bio	N/A	-53.60%	-34.66%

Summary

Turn Therapeutics beats Boundless Bio on 5 of the 9 factors compared between the two stocks.

How does Boundless Bio compare to Hillstream Biopharma?

Boundless Bio (NASDAQ:BOLD) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Hillstream Biopharma's return on equity of -31.50% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Hillstream Biopharma	N/A	-31.50%	-24.72%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Boundless Bio presently has a consensus target price of $4.00, suggesting a potential upside of 60.00%. Given Boundless Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Boundless Bio is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

In the previous week, Boundless Bio had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Hillstream Biopharma. Boundless Bio's average media sentiment score of 1.25 beat Hillstream Biopharma's score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Boundless Bio has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Summary

Boundless Bio beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Anthem?

Boundless Bio (NASDAQ:BOLD) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Anthem's return on equity of -52.35% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Anthem	N/A	-52.35%	-47.25%

Anthem is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

90.5% of Anthem shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 24.5% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Boundless Bio has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Anthem has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

In the previous week, Boundless Bio had 4 more articles in the media than Anthem. MarketBeat recorded 4 mentions for Boundless Bio and 0 mentions for Anthem. Boundless Bio's average media sentiment score of 1.25 beat Anthem's score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Positive
Anthem	Neutral

Boundless Bio currently has a consensus price target of $4.00, suggesting a potential upside of 60.00%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 103.62%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Anthem beats Boundless Bio on 7 of the 12 factors compared between the two stocks.

How does Boundless Bio compare to Spruce Biosciences?

Boundless Bio (NASDAQ:BOLD) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Boundless Bio currently has a consensus target price of $4.00, suggesting a potential upside of 60.00%. Spruce Biosciences has a consensus target price of $163.00, suggesting a potential upside of 210.42%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Boundless Bio had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for Boundless Bio and 1 mentions for Spruce Biosciences. Boundless Bio's average media sentiment score of 1.25 beat Spruce Biosciences' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has higher revenue and earnings than Boundless Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Spruce Biosciences	$4.91M	29.41	-$38.97M	-$36.60	N/A

Boundless Bio has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market.

Boundless Bio's return on equity of -53.60% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Spruce Biosciences	N/A	-155.40%	-101.67%

91.7% of Spruce Biosciences shares are held by institutional investors. 23.1% of Boundless Bio shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Boundless Bio and Spruce Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	PHARMACEUTICAL PREPARATIONS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.16M	$792.30M	$7.18B	$12.47B
Dividend Yield	N/A	4.84%	2.67%	6.50%
P/E Ratio	-1.00	1.66	28.02	24.70
Price / Sales	N/A	116.91	532.59	98.61
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.57	8.17	10.96	6.46
Net Income	-$58.20M	-$3.71M	$3.57B	$337.01M
7 Day Performance	-2.34%	2.59%	2.12%	1.69%
1 Month Performance	76.06%	4.41%	5.25%	3.81%
1 Year Performance	136.97%	49.43%	33.29%	23.90%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	3.831 of 5 stars	$2.50 flat	$4.00 +60.0%	+137.0%	$56.16M	N/A	N/A	64	Positive News Insider Trade
WHWK Whitehawk Therapeutics	2.4391 of 5 stars	$4.11 -6.4%	$8.00 +94.6%	+110.6%	$203.24M	$7.14M	N/A	21	Gap Up High Trading Volume
TTRX Turn Therapeutics	2.1321 of 5 stars	$6.82 +12.0%	$8.00 +17.3%	N/A	$203.15M	N/A	N/A	2	News Coverage Positive News Short Interest Decrease
CNTN Hillstream Biopharma	0.1522 of 5 stars	$2.68 +0.8%	N/A	N/A	$187.09M	N/A	N/A	2	Analyst Upgrade Gap Up
ANTX Anthem	2.1328 of 5 stars	$5.14 -1.2%	$9.00 +75.1%	+309.6%	$185.14M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. WHWK, TTRX, CNTN, ANTX, and SPRB

How does Boundless Bio compare to Whitehawk Therapeutics?

Summary

How does Boundless Bio compare to Turn Therapeutics?

Summary

How does Boundless Bio compare to Hillstream Biopharma?

Summary

How does Boundless Bio compare to Anthem?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. WHWK, TTRX, CNTN, ANTX, and SPRB

How does Boundless Bio compare to Whitehawk Therapeutics?

Which has better earnings and valuation, WHWK or BOLD?

Is WHWK or BOLD more profitable?

Do analysts rate WHWK or BOLD?

Which has more volatility & risk, WHWK or BOLD?

Do insiders & institutionals believe in WHWK or BOLD?

Does the media refer more to WHWK or BOLD?

Summary

How does Boundless Bio compare to Turn Therapeutics?

Does the media prefer TTRX or BOLD?

Do analysts recommend TTRX or BOLD?

Which has better valuation and earnings, TTRX or BOLD?

Is TTRX or BOLD more profitable?

Summary

How does Boundless Bio compare to Hillstream Biopharma?

Is BOLD or CNTN more profitable?

Do insiders & institutionals hold more shares of BOLD or CNTN?

Do analysts prefer BOLD or CNTN?

Which has stronger valuation & earnings, BOLD or CNTN?

Does the media prefer BOLD or CNTN?

Which has more risk and volatility, BOLD or CNTN?

Summary

How does Boundless Bio compare to Anthem?

Is BOLD or ANTX more profitable?

Which has better earnings and valuation, BOLD or ANTX?

Do institutionals and insiders hold more shares of BOLD or ANTX?

Which has more volatility and risk, BOLD or ANTX?

Does the media prefer BOLD or ANTX?

Do analysts prefer BOLD or ANTX?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Do analysts prefer BOLD or SPRB?

Does the media refer more to BOLD or SPRB?

Which has better valuation and earnings, BOLD or SPRB?

Which has more volatility & risk, BOLD or SPRB?

Is BOLD or SPRB more profitable?

Do institutionals & insiders have more ownership in BOLD or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools